Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080220894
JPRN-jRCT2080220894UnknownPhase 2

Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitis

Ajinomoto Pharmaceuticals Co., Ltd.0 sitesStarted: October 19, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 16age old to <= 64age old (—)
Sex
All

Inclusion Criteria

  • •Patients with active-phase ulcerative colitis
  • •- The Mayo score of 6 to 10.
  • •- Inadequate response to or intolerance of appropriate conventional therapy

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Ajinomoto Pharmaceuticals Co., Ltd.

Similar Trials

Unknown
Phase 2
Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitislcerative Colitis
JPRN-jRCT2080222244Ajinomoto Pharmaceuticals Co., Ltd.
Completed
Phase 3
Phase III study of AJM300 in patients with active ulcerative colitis (2)Active Ulcerative Colitis
JPRN-jRCT2080223867EA Pharma Co., Ltd.198
Unknown
Phase 3
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitis
JPRN-jRCT2080222653EA Pharma Co.,Ltd.120
Unknown
Phase 2
Phase-II study of AJA777 in patients with functional dyspepsiaFunctional dyspepsia (recruited according to the ROME III criteria)
JPRN-jRCT2080221822Ajinomoto Pharmaceuticals Co., Ltd.
Unknown
Phase 2
Phase-IIa study of AJA777 in patients with functional dyspepsiaFunctional dyspepsia (recruited according to the ROME III criteria)
JPRN-jRCT2080221048Ajinomoto Pharmaceuticals Co., Ltd.